Shenyang Xingqi Pharmaceutical Co Ltd Working Capital to Net Assets Ratio
Shenyang Xingqi Pharmaceutical Co Ltd working capital to net assets ratio. Shenyang Xingqi Pharmaceutical Co Ltd (300573) has a Working Capital to Net Assets ratio of 24.0% as of September 2025. Working capital of CN¥446.37 Million (current assets of CN¥944.69 Million minus current liabilities of CN¥498.33 Million) is measured against net assets of CN¥1.86 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Shenyang Xingqi Pharmaceutical Co Ltd (300573) tangible equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Shenyang Xingqi Pharmaceutical Co Ltd (2011–2024)
Working capital to net assets ratio of Shenyang Xingqi Pharmaceutical Co Ltd from 2011 to 2024. This chart shows how Shenyang Xingqi Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2011 to 2024. As of September 2025, the ratio stands at 24.0%, reflecting working capital of CN¥446.37 Million against net assets of CN¥1.86 Billion CNY. See 300573 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Shenyang Xingqi Pharmaceutical Co Ltd Working Capital to Net Assets Ratio by Year (2011–2024)
Shenyang Xingqi Pharmaceutical Co Ltd working capital to net assets ratio by year from 2011 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Shenyang Xingqi Pharmaceutical Co Ltd from 2011 to 2024, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Shenyang Xingqi Pharmaceutical Co Ltd total assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 23.1% | CN¥368.44 Million | CN¥1.59 Billion | CN¥829.92 Million | CN¥461.48 Million | ▼ -15.0 pp |
| 2023 | 38.2% | CN¥645.07 Million | CN¥1.69 Billion | CN¥905.19 Million | CN¥260.12 Million | ▼ -7.7 pp |
| 2022 | 45.9% | CN¥712.72 Million | CN¥1.55 Billion | CN¥865.17 Million | CN¥152.45 Million | ▼ -7.5 pp |
| 2021 | 53.4% | CN¥717.59 Million | CN¥1.34 Billion | CN¥984.42 Million | CN¥266.83 Million | ▲ +41.6 pp |
| 2020 | 11.8% | CN¥81.72 Million | CN¥694.06 Million | CN¥294.22 Million | CN¥212.49 Million | ▲ +1.2 pp |
| 2019 | 10.6% | CN¥60.71 Million | CN¥574.90 Million | CN¥281.78 Million | CN¥221.07 Million | ▼ -4.9 pp |
| 2018 | 15.4% | CN¥85.67 Million | CN¥554.58 Million | CN¥209.77 Million | CN¥124.10 Million | ▼ -3.1 pp |
| 2017 | 18.5% | CN¥102.37 Million | CN¥553.38 Million | CN¥194.49 Million | CN¥92.12 Million | ▲ +4.0 pp |
| 2016 | 14.5% | CN¥75.77 Million | CN¥520.95 Million | CN¥243.96 Million | CN¥168.19 Million | ▲ +30.2 pp |
| 2015 | -15.7% | CN¥-61.20 Million | CN¥389.79 Million | CN¥141.97 Million | CN¥203.17 Million | ▲ +3.7 pp |
| 2014 | -19.4% | CN¥-71.42 Million | CN¥367.81 Million | CN¥148.34 Million | CN¥219.76 Million | ▼ -17.4 pp |
| 2013 | -2.0% | CN¥-6.72 Million | CN¥336.80 Million | CN¥138.95 Million | CN¥145.67 Million | ▼ -46.4 pp |
| 2012 | 44.4% | CN¥129.13 Million | CN¥290.70 Million | CN¥184.98 Million | CN¥55.85 Million | ▼ -23.1 pp |
| 2011 | 67.6% | CN¥166.89 Million | CN¥247.00 Million | CN¥182.84 Million | CN¥15.95 Million | — |